Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes
More topics under "A61K - Preparations for medical, dental, or toilet purposes" (2,585,043)
A61K 101 - Radioactive non-metals (526)
A61K 103 - Radioactive metals (481)
A61K 125 - Containing or obtained from roots, bulbs, tubers, corms or rhizomes (2,645)
A61K 127 - Containing or obtained from leaves (1,806)
A61K 129 - Containing or obtained from bark (325)
A61K 131 - Containing or obtained from seeds, nuts, fruits or grains (1,932)
A61K 133 - Containing or obtained from flowers or blossoms (665)
A61K 135 - Containing or obtained from stems, stalks, branches, twigs or shoots (756)
A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
A61K 33 - Medicinal preparations containing inorganic active ingredients (56,213)
A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838)
A61K 36 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines (179,316)
A61K 38 - Medicinal preparations containing peptides (316,240)
A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
A61K 41 - Medicinal preparations obtained by treating materials with wave energy or particle radiation (9,445)
A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
A61K 49 - Preparations for testing in vivo (35,376)
A61K 50 - Electrically conductive preparations for use in therapy or testing in vivo, e.g. conductive adhesives or gels to be used with electrodes for electrocardiography (ecg) or for transcutaneous drug administration (62)
A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
A61K 6 - Preparations for dentistry (18,259)
A61K 8 - Cosmetics or similar toilet preparations (170,551)
A61K 9 - Medicinal preparations characterised by special physical form (299,044)
Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449)
06/2005
06/02/2005US20050119586 Systems and methods for respiratory event detection
06/02/2005US20050119486 Diamine derivatives
06/02/2005US20050119316 Semicarbazide derivatives and the use thereof as antithrombotics
06/02/2005US20050119309 Compositions and methods for selective inhibition of nicotine acetylcholine receptors
06/02/2005US20050119266 Pyrrolidine and piperidine derivatives as factor Xa inhibitors
06/02/2005US20050119243 HIF-1 inhibitors and methods of use thereof
06/02/2005US20050119220 An isolate from the leaves of Gymnema sylvestre obtained by extracting Gymnema sylvestre leaves with aqueous ethanol, removing acid-insoluble salt from the extract, concentrating desalted extract, isolating an insulinotropically active principle
06/02/2005US20050119195 Gastrointestinal disorders
06/02/2005US20050119194 Side effect reduction
06/02/2005US20050119177 Using diketopiperazine; graft versus host disease; autoimmune disease; multiple sclerosis; skin disorders; antiarthritic agents; pancreatitis; inflamamtory bowel disorders
06/02/2005US20050118701 Large scale methods of producing adenovirus and adenovirus seed stocks
06/02/2005US20050118652 Rapid way to obtain high expression clones of mammalian cells using a methylcellulose and immunoprecipitation screening method
06/02/2005US20050118589 Digital array
06/02/2005US20050118567 Method for determining sensitivity to a bacteriophage
06/02/2005US20050118276 Coated metal pyrithione particles for treatment of microorganisms
06/02/2005US20050118267 Chronotherapeutic dosage forms
06/02/2005US20050118254 hydrophilic solvent, an oil, and a surfactant, and a pharmaceutically active component; hydrophilic solvent selected from the group consisting of propylene glycol diacetate, propylene glycol monoacetate, and salts
06/02/2005US20050118217 Rapidly disintegrating films for delivery of pharmaceutical of cosmetic agents
06/02/2005US20050118206 A surfactant, a solvent, and a beneficial agent; exposure to a hydrophilic environment, surfactant and solvent form a viscous gel and beneficial agent dispersed or dissolved in the gel;
06/02/2005US20050118200 Two or more inactivated or attenuated Mycoplasma bovis biotypes, inactivated Mycoplasma alkalescens, an adjuvant and excipient; vaccinating cows; no undesirable side effects and protect against M. bovis related disease, such as contagious mastitis, respiratory pneumonia
06/02/2005US20050118183 Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
06/02/2005US20050118145 Compositions containing sertoli cells and myoid cells and use thereof in cellular transplants
06/02/2005US20050115572 Electrically activated alteration of body tissue stiffness for breathing disorders
06/02/2005CA2547079A1 Dna vaccines encoding hsp60 peptide fragments for treating autoimmune diseases
06/02/2005CA2546210A1 Methods and compositions for the treatment of helicobacter pylori-associated diseases using endoperoxide bridge-containing compounds
06/02/2005CA2545825A1 Hydroxylamine substituted imidazo ring compounds
06/02/2005CA2545819A1 Nutraceutical mangosteen tea
06/02/2005CA2545809A1 Package for pharmaceutical formulation
06/02/2005CA2545806A1 Methods of modulating immunity
06/02/2005CA2545800A1 Surfactant-based gel as an injectable, sustained drug delivery vehicle
06/02/2005CA2545774A1 Oxime substituted imidazo ring compounds
06/02/2005CA2545711A1 Urea derivatives as kinase modulators
06/02/2005CA2543315A1 Methods for treating pain
06/02/2005CA2540159A1 Extended release venlafaxine formulation
06/02/2005CA2533884A1 Preventative effects of morinda citrifolia on mammary breast cancer
06/02/2005CA2532881A1 Anthrax vaccine
06/02/2005CA2515890A1 Novel insertion sites in pox vectors
06/01/2005EP1534749A2 Variant integrin polypeptides and uses thereof
06/01/2005EP1534728A2 Antisense modulation of glucocorticoid receptor expression
06/01/2005EP1534677A1 Piperidine derivatives and their use as selective inhibitors of mip-1alpha binding to its receptor ccr1
06/01/2005EP1534345A2 Method and device for inducing biological processes by micro-organs
06/01/2005EP1534122A2 Medical decision support systems utilizing gene expression and clinical information and method for use
06/01/2005EP1049447B1 Dyeing composition for keratinous fibres with a cationic direct colouring agent and a silicone
06/01/2005EP0991625B1 Inhibitors of factor xa with a neutral p1 specificity group
06/01/2005CN1622995A Receptor nucleic acids and polypeptides
06/01/2005CN1204138C Pyrazolo [4, 3-d] pyrimidine derivs.
06/01/2005CN1203838C Desensitizing dentifrice containing potassium and tin salts
05/2005
05/31/2005US6900327 Used as antidepressants, to treat obsessive compulsive disorder, panic disorders, bulimia, anorexia, pain, obesity, senile demential, migraines, and social phobias
05/31/2005US6899864 Kit and method for targeting of a diagnostic or therapeutic agent to target site in mammal having a pathological condition
05/31/2005CA2324343C C11 oxymyl and hydroxylamino prostaglandins useful as medicaments
05/26/2005WO2005046622A2 Custom vectors for treating and preventing pancreatic cancer
05/26/2005WO2005046621A2 Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines
05/26/2005WO2005046620A2 Variable appearance tissue markings
05/26/2005WO2005046619A2 Compositions and methods for modulating c-rel-dependent cytokine production
05/26/2005WO2005046618A2 Methods of treating eczema
05/26/2005WO2005046617A2 Compositions and methods for reducing microbial induced apoptosis
05/26/2005WO2005046616A2 Viral propagation system and uses thereof
05/26/2005WO2005046615A2 Compositions for treatment of central nervous system mediated disorders
05/26/2005WO2005046614A2 System for treating and preventing breast cancer
05/26/2005WO2005046613A2 Methods and compositions for the treatment of b cell lymphomas and other cancers
05/26/2005WO2005046612A2 Hydroxy piperidine derivatives to treat gaucher disease
05/26/2005WO2005046611A2 Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease
05/26/2005WO2005046610A2 Genes differentially expressed by acutely isolated resident progenitor cells of the human white matter
05/26/2005WO2005046609A2 Process for producing hollow tubular fibers from legume hulls
05/26/2005WO2005046608A2 Novel compound, corresponding compositions, preparation and/or treatment methods
05/26/2005WO2005046606A2 Compositions and methods for diagnosing and treating chronic lymphocytic leukemia
05/26/2005WO2005046605A2 Compositions and methods of treating neurological diseases
05/26/2005WO2005046604A2 Heteroaryl-hydrazone compounds
05/26/2005WO2005046603A2 Pyridine compounds
05/26/2005WO2005046602A2 Vegf receptor antagonists
05/26/2005WO2005046601A2 4-phenyl piperdine sulfonyl glycine transporter inhibitors
05/26/2005WO2005046600A2 Transdermal tulobuterol delivery
05/26/2005WO2005046599A2 Alpha, beta-unsaturated sulfoxides for treating proliferative disorders
05/26/2005WO2005046597A2 Antibodies to cd44 glycoforms and uses thereof
05/26/2005WO2005046596A2 Stem cell culture medium and method of using said medium and the cells
05/26/2005WO2005046595A2 Hif-1 inhibitors and methods of use thereof
05/26/2005WO2005046594A2 Methods of using and compositions comprising a jnk inhibitor for the treatment and management of asbestos-related diseases and disorders
05/26/2005WO2005046593A2 Methods and compositions using thalidomide for the treatment and management of cancers and other diseases.
05/26/2005WO2005046592A2 Methods of using and compositions comprising pde4 modulators for the treatment and management of asbestos-related diseases and disorders
05/26/2005WO2005046591A2 Electrically activated alteration of body tissue stiffness for breathing disorders
05/26/2005WO2005046588A2 Compounds, compositions, and methods
05/26/2005WO2005046587A2 Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
05/26/2005WO2005046586A2 M3 muscarinic acetylcholine receptor antagonists
05/26/2005WO2005046585A2 Vps35-based assays and methods for treating alzheimer’s disease
05/26/2005WO2005046584A2 Stimulation of hair growth by ginkgo biloba flavanoids
05/26/2005WO2005046583A2 Modified fviii having reduced immunogenicity through mutagenesis of a2 and c2 epitopes
05/26/2005WO2005046582A2 Polymeric interpenetrated network carrier and serial polymerization involving a crosslinked polymer network
05/26/2005WO2005046581A2 P18 in stem cell manipulations
05/26/2005WO2005046580A2 Dietary and other compositions, compounds, and methods for reducing body fat, controlling appetite, and modulating fatty acid metabolism
05/26/2005WO2005046578A2 Isoquinolinone potassium channel inhibitors
05/26/2005WO2005046575A2 Amino acid prodrugs
05/26/2005WO2005046573A2 Pro104 ANTIBODY COMPOSITIONS AND METHODS OF USE
05/26/2005WO2005046572A2 Targeted delivery of controlled release polymer systems
05/26/2005WO2005046570A2 Human stem cell materials and methods
05/26/2005WO2005046567A2 Synergistic formulation of antioxidants and antimycobacterial agents: a method of making the same
05/26/2005WO2005046565A2 Diagnosis and treatment of kidney fibrosis and other fibrotic diseases
05/26/2005WO2005046564A2 Diagnosis and treatment of liver fibrosis
05/26/2005WO2005046561A2 Multilayer dosage form comprising a matrix that influences release of a modulatory substance
05/26/2005WO2005046554A2 Altering the stiffness, size, and/or shape of tissues for breathing disorders and other conditions
05/26/2005WO2005030129A3 Quinoline potassium channel inhibitors
1 ... 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 ... 295